Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis

Inactive Publication Date: 2005-02-24
BOEHRINGER INGELHEIM INT GMBH
View PDF7 Cites 129 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

Within the meaning of the present invention, effective amounts of therapeutic agents and/or of a therapeutic treatment by radiotherapy or radio-immunotherapy means

Problems solved by technology

However, proof of efficacy for these substances, used alone or with other cancer therapies, in the treatment of oncological diseases, has so far no

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis
  • Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis
  • Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

The Diseases

As already mentioned hereinbefore, the diseases which can be treated by the combination in accordance with the present invention are all kind of diseases in which cell proliferation, migration or apoptosis of myeloma cells, or angiogenesis are involved, which can be of oncological nature such as all types of malignant neoplasias or cancers, or of non-oncological nature, such as diabetic retinopathy, rheumatoid arthritis, or psoriasis. Among cancers, selected specific target indications are solid tumours, such as urogenital cancers (such as prostate cancer, renal cell cancers, bladder cancers), gynecological cancers (such as ovarian cancers, cervical cancers, endometrial cancers), lung cancer, gastrointestinal cancers (such as colorectal cancers, pancreatic cancer, gastric cancer, oesophageal cancers, hepatocellular cancers, cholangiocellular cancers), head and neck cancer, malignant mesothelioma, breast cancer, malignant melanoma or bone and soft tissue sarcomas, and ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
Timeaaaaaaaaaa
Timeaaaaaaaaaa
Densityaaaaaaaaaa
Login to view more

Abstract

The present invention relates to a pharmaceutical combination for the treatment of diseases which involves cell proliferation, migration or apoptosis of myeloma cells, or angiogenesis. The invention also relates to a method for the treatment of said diseases, comprising co-administration of effective amounts of specific active compounds and/or co-treatment with radiation therapy, in a ratio which provides an additive and synergistic effect, and to the combined use of these specific compounds and/or radiotherapy for the manufacture of corresponding pharmaceutical combination preparations.

Description

FIELD OF THE INVENTION This invention relates to a method for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells, or angiogenesis, which method comprises co-administration to a person in need of such treatment and / or co-treatment of a person in need of such treatment with effective amounts of: (i) a selected protein tyrosine kinase receptor antagonist; and (ii) at least a further chemotherapeutic or naturally occurring, semi-synthetic or synthetic therapeutic agent; and / or (iii) radiotherapy or radio-immunotherapy. This invention relates also to suitable pharmaceutical compositions comprising effective amounts of: (i) a selected protein tyrosine kinase receptor antagonist; and (ii) at least a further chemotherapeutic or naturally occurring, semi-synthetic or synthetic therapeutic agent; and optionally adapted for a co-treatment with radiotherapy or radio-immunotherapy, as a combined preparation for simultaneous, separate or sequen...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K31/496A61K31/517A61K31/56A61K45/06A61P35/00
CPCA61K31/404A61K31/496A61K31/517A61K31/56A61K45/06A61K31/553A61K2300/00A61P17/06A61P19/02A61P27/02A61P29/00A61P3/10A61P35/00A61P35/02A61P43/00A61P9/10
Inventor STEFANIC, MARTIN FRIEDRICHHILBERG, FRANKMUNZERT, GERDSOLCA, FLAVIOBAUM, ANKEVAN MEEL, JACOBUS C.A.
Owner BOEHRINGER INGELHEIM INT GMBH
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products